In a market defined by unpredictability, volatility, and fast-paced evolution, it can be challenging to determine where it’s heading and what executives should concern themselves with in the second half of 2024 and beyond. Interest in obesity drugs has led to billions of new prescriptions of GLP-1s, like Wegovy and Ozempic (and consequently, an endless cash flow of revenue for pharma companies,) while geopolitical tensions in China and Ukraine have muddied waters for manufacturers.
We’ve combed through thousands of corporate earnings call transcripts, interviews from our expert call library, research documents, and more—all found within AlphaSense—to identify the top market-moving trends to keep an eye on for H2 2024.
In this report, discover:
- How corporations are tackling supply chain stalls brought on by global warfare with reshoring—a tactic to reinvigorate domestic manufacturing
- The natural resource C-suite executives are discussing to reduce their carbon footprint, operate on clean energy, and embrace a net-zero future
- Technology that is dramatically altering how business is being conducted in every industry, from IT to legal, talent acquisition and even financial services